Pharmaceutical industry influence over the information doctors receive in the classroom has more than tripled in the last decade, to $1.2 billion, making it hard to determine whether medical professionals are learning science or getting fed marketing gimmicks, doctors and health professionals told a Senate panel Wednesday.
In a practice called Continuing Medical Education, or CME, doctors take classes and training courses to stay current on the best ways to treat patients. Many states and hospitals require doctors to take such classes. The problem, as Congress and some health professionals see it, is that the pharmaceutical industry now funds more than half these courses, at the pace of $1.2 billion a year.
"CME has become an insidious vehicle for the aggressive promotion of drugs and medical devices," said Dr. Steve Nissen, a cardiologist from the Cleveland Clinic who is best known for first raising concerns about heart attacks associated with the blockbuster diabetes drug Avandia.
Lewis Morris, chief counsel for the Department of Health and Human Services Office of Inspector General, said there are numerous examples where companies have used CME courses to promote off-label uses of their products, which is illegal.
money.cnn.com
Pharmaceutical Process Equipment
Friday, 31 July 2009
Wednesday, 29 July 2009
The National Pandemic Flu Service
The National Pandemic Flu Service has been launched in England.
If you are in England and feel like you may have swine flu, visit the new website by following the link below, or call 0800 1 513 100 (Textphone - 0800 1 513 200).
www.direct.gov.uk
People who have swine flu symptoms will be given a unique access number and told where their nearest antiviral collection point is. They should then ask a flu friend - a friend or relative who doesn't have swine flu - to go and pick up their antivirals. The flu friend must show their own ID as well as that of the patient.
Contact your doctor directly rather than using the National Pandemic Flu Service if:
- you have a serious underlying illness
- you are pregnant
- you have a sick child under one year old
- your condition suddenly gets much worse
- your condition is still getting worse after 7 days (5 for a child).
http://www.direct.gov.uk/en/Swineflu/DG_177831
Saturday, 25 July 2009
Swine flu vaccines will cost €80m
THE SWINE flu pandemic will lead to one of the biggest vaccination programmes in the history of the State.
In the coming months, everyone in the country will be offered two doses of a vaccine which is still being developed by the pharmaceutical giants charged with bringing it to the market.
The vaccine the world is waiting for has not been developed yet but Dr Patrick Doorley, the HSE’s national director of population health, said he is certain there will be one. “First of all you have to identify the exact nature of the virus. That is why we did not have a vaccine before this happened. The big companies have all got the seeds now. We will have a vaccine. These companies are well used to making them,” he said.
In total, 7.7 million vaccines will be bought from three foreign pharmaceutical companies – GlaxoSmith-Kline, Baxter Healthcare and Allphar Services – at a combined cost of around €80 million.
There will be enough to immunise 3.85 million people, though the plan is to immunise everybody. There have been around 150 confirmed cases, but no deaths, to date in Ireland.
www.irishtimes.com
In the coming months, everyone in the country will be offered two doses of a vaccine which is still being developed by the pharmaceutical giants charged with bringing it to the market.
The vaccine the world is waiting for has not been developed yet but Dr Patrick Doorley, the HSE’s national director of population health, said he is certain there will be one. “First of all you have to identify the exact nature of the virus. That is why we did not have a vaccine before this happened. The big companies have all got the seeds now. We will have a vaccine. These companies are well used to making them,” he said.
In total, 7.7 million vaccines will be bought from three foreign pharmaceutical companies – GlaxoSmith-Kline, Baxter Healthcare and Allphar Services – at a combined cost of around €80 million.
There will be enough to immunise 3.85 million people, though the plan is to immunise everybody. There have been around 150 confirmed cases, but no deaths, to date in Ireland.
www.irishtimes.com
Friday, 24 July 2009
The Changing Landscape of Pharmaceutical Marketing
The shift of the pharmaceutical industry from one based on blockbuster drugs to one based on smaller, niche medicines is affecting not just companies’ R&D strategies, but also how companies are marketing their drugs.
We spoke to Rebecca Robins, the global marketing director at Interbrand Health, an international branding agency, about how branding and marketing in the pharmaceutical industry is changing. She has helped brand several big drug blockbusters, including Bristol-Myers’ Plavix, the world’s second largest drug by sales.
One of the main differences that she sees today is that companies “are coming to us earlier in their pipeline” with drugs in their mid-stage development rather than waiting until the late stages as they did 10 years ago. Now facing markets more crowded with competitors, the companies are beginning to shape a brand for its experimental medicine with Phase II data in hand, much earlier than if they waited until they had late-stage study results.
This gives companies “critical extra years to shape and condition the market,” said Robins.
blogs.wsj.com
We spoke to Rebecca Robins, the global marketing director at Interbrand Health, an international branding agency, about how branding and marketing in the pharmaceutical industry is changing. She has helped brand several big drug blockbusters, including Bristol-Myers’ Plavix, the world’s second largest drug by sales.
One of the main differences that she sees today is that companies “are coming to us earlier in their pipeline” with drugs in their mid-stage development rather than waiting until the late stages as they did 10 years ago. Now facing markets more crowded with competitors, the companies are beginning to shape a brand for its experimental medicine with Phase II data in hand, much earlier than if they waited until they had late-stage study results.
This gives companies “critical extra years to shape and condition the market,” said Robins.
blogs.wsj.com
Thursday, 23 July 2009
Pharmaceutical to market blood pressure pill in Canada
Mississauga-based Ranbaxy Pharmaceuticals-Canada Inc. will be manufacturing and marketing Ran-Amlodipine tablets.
The Canadian subsidiary of India's largest pharmaceutical company, Ranbaxy Laboratories Limited, announced today it received final approval from Health Canada to make and market pills that help high blood pressure and chest pains caused by an insufficient supply of blood to the heart muscle.
Paul Drake, the president of Ranbaxy Pharmaceuticals-Canada Inc. on Matheson Blvd. E., says they're looking forward to marketing Ran-Amlodipine tablets as an antihypertensive-antianginal pill.
mississauganews.com
The Canadian subsidiary of India's largest pharmaceutical company, Ranbaxy Laboratories Limited, announced today it received final approval from Health Canada to make and market pills that help high blood pressure and chest pains caused by an insufficient supply of blood to the heart muscle.
Paul Drake, the president of Ranbaxy Pharmaceuticals-Canada Inc. on Matheson Blvd. E., says they're looking forward to marketing Ran-Amlodipine tablets as an antihypertensive-antianginal pill.
mississauganews.com
Wednesday, 22 July 2009
You can now find Hanningfield Process Systems on Facebook!
You can now find Hanningfield Process Systems on Facebook!
Click here to become a fan and you will be able to get first hand, up to date information regarding all of Hanningfield's lastest products and events!
Our profile also showcases pictures of all of our products and provides relevant information regarding our products and services.
In addition to this, you will be able to follow our status updates, allowing you to follow the goings on here at Hanningfield.
Click here to become a fan and you will be able to get first hand, up to date information regarding all of Hanningfield's lastest products and events!
Our profile also showcases pictures of all of our products and provides relevant information regarding our products and services.
In addition to this, you will be able to follow our status updates, allowing you to follow the goings on here at Hanningfield.
Tuesday, 21 July 2009
Hanningfield Adds YouTube Channel
Hanningfield are glad to announce the launch of their YouTube channel, which will showcase various products to help highlight their benefit to your process and will contain other helpful processing information.
Whilst there are currently no uploaded videos, please be assured there are plans to add content over the coming weeks.
Whilst there are currently no uploaded videos, please be assured there are plans to add content over the coming weeks.
Wednesday, 8 July 2009
Hanningfield seeking agents
Hanningfield Process Systems is proud to have it's equipment installed around the world.
To help continue this trend we are actively seeking more agents and partnerships; with a particular focus on Europe and North America, but in all other regions also.If you are interested in such a proposition and would like more information, please feel free to contact Hanningfield using the enquiry form.
To help continue this trend we are actively seeking more agents and partnerships; with a particular focus on Europe and North America, but in all other regions also.If you are interested in such a proposition and would like more information, please feel free to contact Hanningfield using the enquiry form.
Tuesday, 7 July 2009
Vaccine Market to Drive Future Pharmaceutical Growth
The worldwide vaccine market has undergone a rapid transformation phase over the last few years. In the present scenario, major pharmaceutical players are eyeing vaccine market for their growth.
The global vaccine sales grew at a CAGR of around 28% during 2005-2008, reveals our new research report “Global Vaccine Market Forecast to 2012”.
According to the report, the leading pharmaceutical companies such as Sanofi Aventis, Glaxo Smith Kline, Merck and Wyeth made significant investments in R&D that brought the major turnaround in the market and the market size surpassed US$ 20 Billion in 2008.
Also, the introduction of cancer and rotavirus vaccines helped the global vaccine market to boost significantly.
emailwire.com
The global vaccine sales grew at a CAGR of around 28% during 2005-2008, reveals our new research report “Global Vaccine Market Forecast to 2012”.
According to the report, the leading pharmaceutical companies such as Sanofi Aventis, Glaxo Smith Kline, Merck and Wyeth made significant investments in R&D that brought the major turnaround in the market and the market size surpassed US$ 20 Billion in 2008.
Also, the introduction of cancer and rotavirus vaccines helped the global vaccine market to boost significantly.
emailwire.com
Friday, 3 July 2009
Flu vaccine available in October.
There is no indication the A(H1N1) virus has mutated in Thailand and a vaccine is expected to be available in October, Public Health Minister Witthaya Kaewparadai said on Tuesday that he was confident the swine flu outbreak could still be contained & people with flu-like symptoms should visit hospitals quickly if the symptoms do not subside in two days.
A vaccine against the A(H1N1) virus should be available by October, and the government would initially import 12 million doses at a cost of about two million baht.
The Government Pharmaceutical Organisation and Silpakorn University would also jointly research a vaccine for use against the virus.
The Bureau of Epidemiology said that cases of human-to-human transmission could be expected to increase this month. People should take precautions by washing their hands regularly and wearing face masks in public places.
bangkokpost.com
A vaccine against the A(H1N1) virus should be available by October, and the government would initially import 12 million doses at a cost of about two million baht.
The Government Pharmaceutical Organisation and Silpakorn University would also jointly research a vaccine for use against the virus.
The Bureau of Epidemiology said that cases of human-to-human transmission could be expected to increase this month. People should take precautions by washing their hands regularly and wearing face masks in public places.
bangkokpost.com
Thursday, 2 July 2009
Singapore’s Production Unexpectedly Gains on Pharmaceuticals.
Singapore’s industrial production unexpectedly increased in May as pharmaceutical companies boosted output.
Manufacturing, which accounts for about a quarter of Singapore’s economy, rose 2 percent from a year earlier following a revised 0.4 percent gain in April, the Economic Development Board said today. The median forecast in a Bloomberg News survey of seven economists was for a drop of 3 percent.
Singapore’s government said last month the nation may have “hit the bottom” of its deepest recession since independence in 1965. The narrowing of declines in the island’s exports and production has been helped by gains in pharmaceutical shipments, an industry economists describe as “volatile.”
“The pharmaceutical industry may have gotten a boost from demand for vaccines and other drugs amid the swine flu,” said Alvin Liew, an economist at Standard Chartered Bank in Singapore. “The broad picture shows that you can’t run away from the fact that electronics are still weak. I’m quite doubtful that this pace of recovery can be maintained.”
bloomberg.com
Manufacturing, which accounts for about a quarter of Singapore’s economy, rose 2 percent from a year earlier following a revised 0.4 percent gain in April, the Economic Development Board said today. The median forecast in a Bloomberg News survey of seven economists was for a drop of 3 percent.
Singapore’s government said last month the nation may have “hit the bottom” of its deepest recession since independence in 1965. The narrowing of declines in the island’s exports and production has been helped by gains in pharmaceutical shipments, an industry economists describe as “volatile.”
“The pharmaceutical industry may have gotten a boost from demand for vaccines and other drugs amid the swine flu,” said Alvin Liew, an economist at Standard Chartered Bank in Singapore. “The broad picture shows that you can’t run away from the fact that electronics are still weak. I’m quite doubtful that this pace of recovery can be maintained.”
bloomberg.com
Wednesday, 1 July 2009
Awards ceremony celebrates pharmaceutical companies
An awards show has recognised the contribution of pharmaceutical professionals and gave out accolades to celebrate their achievements over the last year.
The European Mediscience Awards Dinner 2009 took place in London over the weekend and was hosted by the BBC Breakfast presenter Kate Silverton.A top accolade of Company of the Year was awarded to the Austrian vaccine company Intercell, which received approval from the US Food and Drug Administration for its Japanese encephalitis vaccine in record time.
David Wilson, chief executive of Piper Jaffray, which is an investment bank and sponsored the Company of the Year award, said: "There are now 836 Mediscience companies listed throughout Europe. This is a massive increase from the equivalent figure of 503 seen last year, despite the impact that the global recession in other market areas."
He added that the vast array of pharmaceutical companies gave judges a rich and diverse range of nominees to choose from.In other pharmaceutical award news, drugmaker Amgen has recently given more than $10,000 (£6,084) to science teachers which the company believes have helped to develop the next generation of pharmaceutical professionals.
The European Mediscience Awards Dinner 2009 took place in London over the weekend and was hosted by the BBC Breakfast presenter Kate Silverton.A top accolade of Company of the Year was awarded to the Austrian vaccine company Intercell, which received approval from the US Food and Drug Administration for its Japanese encephalitis vaccine in record time.
David Wilson, chief executive of Piper Jaffray, which is an investment bank and sponsored the Company of the Year award, said: "There are now 836 Mediscience companies listed throughout Europe. This is a massive increase from the equivalent figure of 503 seen last year, despite the impact that the global recession in other market areas."
He added that the vast array of pharmaceutical companies gave judges a rich and diverse range of nominees to choose from.In other pharmaceutical award news, drugmaker Amgen has recently given more than $10,000 (£6,084) to science teachers which the company believes have helped to develop the next generation of pharmaceutical professionals.
Subscribe to:
Posts (Atom)